Voyager Acquisition Corp./Cayman Islands (VACHW) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
C/O WINSTON & STRAWN LLP HOUSTON, TX 77002 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 668 | |||
| Cash and cash equivalent | 668 | |||
| Prepaid expense | ||||
| Other undisclosed current assets | 44 | |||
| Total current assets: | 712 | |||
| Noncurrent Assets | ||||
| Intangible asset, including goodwill, after accumulated amortization | 5,000 | |||
| Intangible asset, excluding goodwill, after accumulated amortization | 5,000 | |||
| Other undisclosed noncurrent assets | 254,100 | |||
| Total noncurrent assets: | 259,100 | |||
| TOTAL ASSETS: | 259,812 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities, including: | 5 | |||
| Other undisclosed accounts payable and accrued liabilities | 5 | |||
| Other undisclosed current liabilities | 34 | |||
| Total current liabilities: | 39 | |||
| Noncurrent Liabilities | ||||
| Other undisclosed noncurrent liabilities | 12,045 | |||
| Total noncurrent liabilities: | 12,045 | |||
| Total liabilities: | 12,084 | |||
| Equity | ||||
| Equity, attributable to parent, including: | (11,372) | |||
| Accumulated deficit | (11,372) | |||
| Other undisclosed equity, attributable to parent | 1 | |||
| Other undisclosed equity | 259,100 | |||
| Total equity: | 247,728 | |||
| TOTAL LIABILITIES AND EQUITY: | 259,812 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
| Revenues (Other Income) | 10 | ||
| Gross profit: | 10 | ||
| Operating expenses | (10) | ||
| Other operating expense, net (Other Expenses) | |||
| Other undisclosed operating loss | (703) | ||
| Operating loss: | (703) | ||
| Nonoperating income | |||
| Income (loss) from continuing operations: | (703) | ||
| Other undisclosed net income | 4,844 | ||
| Net income available to common stockholders, diluted: | 4,141 | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
| Net income: | 4,141 | ||
| Comprehensive income, net of tax, attributable to parent: | 4,141 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.